Drug Trial Radar · NCT05393037
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
313
Actual
Start
Jul 13, 2022
Primary completion
Jul 13, 2023
Study completion Jan 25, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.
Conditions
- Pneumococcal Disease
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PlaceboBiological
Saline in each 0.5 mL sterile solution
PCV15Biological
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
PPSV23Biological
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
PCV15 - Part BBiological
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part ATime frame: Up to 5 days after each vaccination in Part A
- Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part ATime frame: Up to 5 days after each vaccination in Part A
- Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part ATime frame: Up to 194 days in Part A
- Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116Time frame: Up to 114 days
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Pueblo Family Physicians ( Site 0014)
Phoenix, Arizona
Whitman-Walker Institute ( Site 0009)
Washington D.C., District of Columbia
Midway Immunology and Research Center ( Site 0003)
Ft. Pierce, Florida
Orlando Immunology Center ( Site 0004)
Orlando, Florida
KC CARE Health Center ( Site 0013)
Kansas City, Missouri
North Texas Infectious Diseases Consultants, P.A ( Site 0001)
Dallas, Texas
Texas Center for Infectious Disease Associates ( Site 0011)
Fort Worth, Texas
Insituut voor tropische Geneeskunde ( Site 0501)
Antwerp, Belgium
CHU Saint-Pierre ( Site 0500)
Brussels, Bruxelles-Capitale, Region de, Belgium
Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0101)
Temuco, Araucania, Chile
Universidad San Sebastian - Providencia ( Site 0111)
Providencia, Region M. de Santiago, Chile
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107)
Santiago, Region M. de Santiago, Chile
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0601)
Paris, France
Hôpital Saint-Louis ( Site 0600)
Paris, Île-de-France Region, France
Josha Research ( Site 0900)
Bloemfontein, Free State, South Africa
Perinatal HIV Research Unit (PHRU)-Adult Treatment and Research ( Site 0906)
Johannesburg, Gauteng, South Africa
Right To Care Research - Esizayo ( Site 0904)
Johannesburg, Gauteng, South Africa
Be Part Yoluntu Centre ( Site 0902)
Paarl, Western Cape, South Africa
Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 1101
Chiang Mai, Thailand
Faculty of Medicine Siriraj Hospital-Preventive and social ( Site 1100)
Bangkok, Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.